IDH2 and glioma: While the specific mechanism of IDH mutation that results in the oncogenic switch in gliomas remains unknown, potential mechanisms have been identified, including the inhibition of hypoxia-related proline hydroxylases, inhibition of DNA demethylases, inhibition of histone demethylases, and alterations in glutamate metabolism.